

# Patrick P J Phillips

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5428319/publications.pdf>

Version: 2024-02-01

91  
papers

5,307  
citations

117453

34  
h-index

88477

70  
g-index

95  
all docs

95  
docs citations

95  
times ranked

5457  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Impact of the Line Probe Assay and Xpert <sup>®</sup> MTB/RIF Assay in the Presumptive Diagnosis of Drug-Resistant Tuberculosis in Brazil: A Pragmatic Clinical Trial. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2022, 55, e0191.	0.4	3
2	Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, 1594-1601.	2.9	12
3	MOVER approximated CV: A tool for quantifying precision in ratiometric droplet digital PCR assays. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 212, 114664.	1.4	0
4	Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomized controlled trial. <i>Trials</i> , 2022, 23, 399.	0.7	2
5	Optimising pyrazinamide for the treatment of tuberculosis. <i>European Respiratory Journal</i> , 2021, 58, 2002013.	3.1	15
6	Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg <sup>-1</sup> rifampicin. <i>European Respiratory Journal</i> , 2021, 58, 2000955.	3.1	32
7	Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	10
8	Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. <i>New England Journal of Medicine</i> , 2021, 384, 1705-1718.	13.9	259
9	Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1086-1096.	2.5	17
10	A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials. <i>Trials</i> , 2021, 22, 515.	0.7	6
11	Noninferiority Trials. , 2021, , 1-28.		1
12	Completion of isoniazid+rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness implementation randomized trial. <i>PLoS Medicine</i> , 2021, 18, e1003875.	3.9	6
13	Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	2
14	Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 598-605.	2.5	7
15	Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay. <i>Thorax</i> , 2020, 75, 606-608.	2.7	49
16	Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. <i>Implementation Science</i> , 2020, 15, 65.	2.5	8
17	High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. <i>Contemporary Clinical Trials</i> , 2020, 90, 105938.	0.8	36
18	Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 305-306.	2.5	0

#	ARTICLE	IF	CITATIONS
19	Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial. <i>Bulletin of the World Health Organization</i> , 2020, 98, 306-314.	1.5	15
20	Experiences of living with varicose veins: A systematic review of qualitative research. <i>Journal of Clinical Nursing</i> , 2019, 28, 1085-1099.	1.4	14
21	Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. <i>European Respiratory Journal</i> , 2019, 54, 1900982.	3.1	14
22	Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. <i>BMC Pulmonary Medicine</i> , 2019, 19, 152.	0.8	1
23	STREAM: a pragmatic and explanatory trial for MDR-TB treatment. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 575-576.	4.6	1
24	Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening. <i>Diagnostics</i> , 2019, 9, 56.	1.3	2
25	Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape. <i>PLoS Medicine</i> , 2019, 16, e1002767.	3.9	20
26	A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. <i>New England Journal of Medicine</i> , 2019, 380, 1201-1213.	13.9	275
27	Proposals on Kaplan-Meier plots in medical research and a survey of stakeholder views: KMunicate. <i>BMJ Open</i> , 2019, 9, e030215.	0.8	33
28	Q fever—the superstition of avoiding the word “quiet” as a coping mechanism: randomised controlled non-inferiority trial. <i>BMJ</i> , The, 2019, 367, l6446.	3.0	9
29	Protein binding of rifampicin is not saturated when using high-dose rifampicin. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 986-990.	1.3	13
30	The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, 34-41.	2.9	80
31	Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. <i>BMC Medicine</i> , 2018, 16, 46.	2.3	46
32	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 265-275.	5.2	80
33	A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. <i>Nature Medicine</i> , 2018, 24, 1708-1715.	15.2	219
34	Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	18
35	Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. <i>BMC Infectious Diseases</i> , 2018, 18, 317.	1.3	16
36	Rethinking non-inferiority: a practical trial design for optimising treatment duration. <i>Clinical Trials</i> , 2018, 15, 477-488.	0.7	20

#	ARTICLE	IF	CITATIONS
37	Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial. <i>BMC Medicine</i> , 2017, 15, 71.	2.3	57
38	Setting Tuberculosis Regimen Development on a Firm Foundation. <i>Clinical Infectious Diseases</i> , 2017, 65, 55-56.	2.9	2
39	Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. <i>Clinical Trials</i> , 2017, 14, 451-461.	0.7	59
40	Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.3	48
41	High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 39-49.	4.6	294
42	Spot sputum samples are at least as good as early morning samples for identifying <i>Mycobacterium tuberculosis</i> . <i>BMC Medicine</i> , 2017, 15, 192.	2.3	12
43	A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens. <i>BMC Medicine</i> , 2017, 15, 207.	2.3	12
44	An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 563.	0.7	17
45	OP27 Patient-Reported Outcome Measures In Carotid Artery Revascularization. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 12-13.	0.2	1
46	IMPACT OF MOLECULAR GENETIC METHODS ON THE INITIATION OF CHEMOTHERAPY IN MULTIPLE DRUG RESISTANT TUBERCULOSIS PATIENTS IN ARKHANGELSK REGION. <i>Tuberculosis and Lung Diseases</i> , 2017, 95, 10-17.	0.2	5
47	The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. <i>PLoS ONE</i> , 2016, 11, e0152761.	1.1	23
48	Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes. <i>Trials</i> , 2016, 17, 309.	0.7	16
49	Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. <i>BMJ Open</i> , 2016, 6, e012594.	0.8	105
50	World TB Day 2016: an interview with leading experts in tuberculosis research. <i>BMC Medicine</i> , 2016, 14, 55.	2.3	2
51	Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. <i>BMC Medicine</i> , 2016, 14, 19.	2.3	56
52	A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). <i>BMC Medicine</i> , 2016, 14, 51.	2.3	25
53	Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. <i>European Respiratory Journal</i> , 2016, 47, 1591-1592.	3.1	7
54	Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 290-294.	0.6	18

#	ARTICLE	IF	CITATIONS
55	Challenges in the clinical assessment of novel tuberculosis drugs. <i>Advanced Drug Delivery Reviews</i> , 2016, 102, 116-122.	6.6	25
56	Safe and effective treatment for patients with isoniazid drug resistance. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 494-495.	0.6	0
57	Comments on "A modest proposal for dropping poor arms in clinical trials" by Proschan and Dodd. <i>Statistics in Medicine</i> , 2015, 34, 2678-2679.	0.8	1
58	Reducing relapse in tuberculosis treatment. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1263-1264.	0.6	1
59	Shortening treatment of tuberculosis: lessons from fluoroquinolone trials. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 141-143.	4.6	17
60	Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1558-1566.	1.3	77
61	The relationship between <i>Mycobacterium tuberculosis</i> MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 448-455.	1.3	58
62	A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1058-1065.	2.5	260
63	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurology</i> , The, 2015, 14, 1171-1181.	4.9	124
64	A Step toward an Optimized Rifampin Dose Completed. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 525-526.	2.5	7
65	Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 353.	0.7	110
66	Principles for designing future regimens for multidrug-resistant tuberculosis. <i>Bulletin of the World Health Organization</i> , 2014, 92, 68-74.	1.5	60
67	High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. <i>New England Journal of Medicine</i> , 2014, 371, 1599-1608.	13.9	383
68	Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. <i>New England Journal of Medicine</i> , 2014, 371, 1577-1587.	13.9	551
69	The Molecular Bacterial Load Assay Replaces Solid Culture for Measuring Early Bactericidal Response to Antituberculosis Treatment. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3064-3067.	1.8	62
70	Short Intensified Treatment in Children with Drug-susceptible Tuberculous Meningitis. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 993.	1.1	1
71	Randomized clinical trials to identify optimal antibiotic treatment duration. <i>Trials</i> , 2013, 14, 88.	0.7	14
72	A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis. <i>BMC Medical Research Methodology</i> , 2013, 13, 139.	1.4	34

#	ARTICLE	IF	CITATIONS
73	Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. <i>Lancet Respiratory Medicine</i> , 2013, 1, 462-470.	5.2	151
74	Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months? [Short communication]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 807-809.	0.6	10
75	Reply to Dodd and Proschan. <i>Journal of Infectious Diseases</i> , 2013, 207, 544-545.	1.9	0
76	An Analysis With Serious Flaws. <i>Clinical Infectious Diseases</i> , 2013, 57, 1064-1065.	2.9	2
77	Treatment of pulmonary tuberculosis. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 273-279.	1.2	9
78	An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse. <i>PLoS ONE</i> , 2013, 8, e63840.	1.1	69
79	Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis. <i>Journal of Infectious Diseases</i> , 2012, 205, S250-S257.	1.9	58
80	When inferiority meets non-inferiority: Implications for interim analyses. <i>Clinical Trials</i> , 2012, 9, 605-609.	0.7	16
81	Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 366, 893-903.	13.9	626
82	Determining the minimum clinically important differences for outcomes in the DOMINO trial. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 812-817.	1.3	126
83	Molecular Bacterial Load Assay, a Culture-Free Biomarker for Rapid and Accurate Quantification of Sputum <i>Mycobacterium tuberculosis</i> Bacillary Load during Treatment. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3905-3911.	1.8	97
84	Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 972-979.	2.5	52
85	Bactericidal activity of the diarylquinoline TMC207 against <i>Mycobacterium tuberculosis</i> outside and within cells. <i>Tuberculosis</i> , 2010, 90, 301-305.	0.8	49
86	Impact of Cotrimoxazole on Carriage and Antibiotic Resistance of <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> in HIV-Infected Children in Zambia. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3756-3762.	1.4	40
87	Challenges of Phase III study design for trials of new drug regimens for the treatment of TB. <i>Future Medicinal Chemistry</i> , 2010, 2, 1273-1282.	1.1	6
88	Biomarkers for tuberculosis disease activity, cure, and relapse. <i>Lancet Infectious Diseases</i> , 2010, 10, 69-70.	4.6	17
89	DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT. <i>Trials</i> , 2009, 10, 57.	0.7	44
90	Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). <i>Tuberculosis</i> , 2008, 88, S85-S92.	0.8	38

#	ARTICLE	IF	CITATIONS
91	Biomarkers and Surrogate End Points in Clinical Trials of Tuberculosis Treatment. Journal of Infectious Diseases, 2007, 196, 648-649.	1.9	6